Evidence map›Paper›PMID 27459660›Full record

ArticleJournal of managed care & specialty pharmacy2016

Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.

Albert J Farias, Ryan N Hansen, Steven B Zeliadt, India J Ornelas, Christopher I Li, Beti Thompson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Albert J Farias1 Department of Epidemiology and Human Genetics, University of Texas Health Sciences Center at Houston, School of Public Health, Houston, Texas.
Ryan N Hansen2 Department of Health Services, University of Washington, Seattle.
Steven B Zeliadt3 Department of Health Services, University of Washington, Seattle, and Health Services Research and Development Center of Excellence, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
India J Ornelas2 Department of Health Services, University of Washington, Seattle.
Christopher I Li4 Department of Epidemiology, University of Washington, Seattle, and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Beti Thompson5 Department of Health Services, University of Washington, Seattle, and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Fred Hutch Cancer Center · USUniversity of Washington · USThe University of Texas Health Science Center at Houston · USVA Puget Sound Health Care System · US

Funding

BEHAVIORAL SCIENCE EDUCATION--CANCER PREVENTION/CONTROLR25CA057712 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MULLEN, PATRICIA DOLAN · 1992 to 2017
$8.6M
Addressing Disparities in Breast Cancer Outcomes among Hispanic WomenF31CA174338 · NCI · UNIVERSITY OF WASHINGTON · PI FARIAS, ALBERT JOHN · 2012 to 2015
$120k
NCI NIH HHS F31 CA174338NCI NIH HHS R25 CA057712
6 · The paper itself

Abstract

backgroundAdherence to adjuvant endocrine therapy (AET) for estrogen receptor-positive breast cancer remains suboptimal, which suggests that women are not getting the full benefit of the treatment to reduce breast cancer recurrence and mortality. The majority of studies on adherence to AET focus on identifying factors among those women at the highest levels of adherence and provide little insight on factors that influence medication use across the distribution of adherence.

objectiveTo understand how factors influence adherence among women across low and high levels of adherence.

methodsA retrospective evaluation was conducted using the Truven Health MarketScan Commercial Claims and Encounters Database from 2007-2011. Privately insured women aged 18-64 years who were recently diagnosed and treated for breast cancer and who initiated AET within 12 months of primary treatment were assessed. Adherence was measured as the proportion of days covered (PDC) over a 12-month period. Simultaneous multivariable quantile regression was used to assess the association between treatment and demographic factors, use of mail order pharmacies, medication switching, and out-of-pocket costs and adherence. The effect of each variable was examined at the 40th, 60th, 80th, and 95th quantiles.

resultsAmong the 6,863 women in the cohort, mail order pharmacies had the greatest influence on adherence at the 40th quantile, associated with a 29.6% (95% CI = 22.2-37.0) higher PDC compared with retail pharmacies. Out-of-pocket cost for a 30-day supply of AET greater than $20 was associated with an 8.6% (95% CI = 2.8-14.4) lower PDC versus $0-$9.99. The main factors that influenced adherence at the 95th quantile were mail order pharmacies, associated with a 4.4% higher PDC (95% CI = 3.8-5.0) versus retail pharmacies, and switching AET medication 2 or more times, associated with a 5.6% lower PDC versus not switching (95% CI = 2.3-9.0).

conclusionsFactors associated with adherence differed across quantiles. Addressing the use of mail order pharmacies and out-of-pocket costs for AET may have the greatest influence on improving adherence among those women with low adherence. DISCLOSURES: This research was supported by a Ruth L. Kirschstein National Research Service Award for Individual Predoctoral Fellowship grant from the National Cancer Institute (grant number F31 CA174338), which was awarded to Farias. Additionally, Farias was funded by a Postdoctoral Fellowship at the University of Texas School of Public Health Cancer Education and Career Development Program through the National Cancer Institute (NIH Grant R25 CA57712). The other authors declare no conflicts of interest. DISCLAIMER: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Farias was primarily responsible for the study concept and design, along with Hansen and Zeliadt and with assistance from the other authors. Farias, Hansen, and Zeliadt took the lead in data interpretation, assisted by the other authors. The manuscript was written by Farias, along with Thompson and assisted by the other authors, and was revised by Ornelas, Li, and Farias, with assistance from the other authors.

Indexed as

Medication AdherenceAdolescentAdultAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCohort StudiesEstrogen AntagonistsFemaleFollow-Up StudiesHumansInsurance, HealthMiddle AgedRegression AnalysisRetrospective StudiesTamoxifenAromatase InhibitorsEstrogen AntagonistsTamoxifen

Identifiers

PMID27459660
PMCPMC4978119
OpenAlexW2500857994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.